128 related articles for article (PubMed ID: 35491356)
21. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
22. Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study.
Shui IM; Liu XQ; Zhao Q; Kim ST; Sun Y; Yearley JH; Choudhury T; Webber AL; Krepler C; Cristescu R; Lee J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793874
[TBL] [Abstract][Full Text] [Related]
23. Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer.
Manogue C; Cotogno P; Ledet E; Lewis B; Wyatt AW; Sartor O
Oncologist; 2019 Apr; 24(4):444-448. PubMed ID: 30541755
[TBL] [Abstract][Full Text] [Related]
24. Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.
Joshi M; Grivas P; Mortazavi A; Monk P; Clinton SK; Sue-Ann Woo M; Holder SL; Drabick JJ; Yin M
Cancer Med; 2020 Dec; 9(24):9365-9372. PubMed ID: 33098265
[TBL] [Abstract][Full Text] [Related]
25. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW
Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).
Templeton AJ; Dutoit V; Cathomas R; Rothermundt C; Bärtschi D; Dröge C; Gautschi O; Borner M; Fechter E; Stenner F; Winterhalder R; Müller B; Schiess R; Wild PJ; Rüschoff JH; Thalmann G; Dietrich PY; Aebersold R; Klingbiel D; Gillessen S;
Eur Urol; 2013 Jul; 64(1):150-8. PubMed ID: 23582881
[TBL] [Abstract][Full Text] [Related]
27. Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry.
Notohardjo JCL; Kuppen MCP; Westgeest HM; van Moorselaar RJA; Mehra N; Coenen JLLM; van Oort IM; de Vos AI; Vervenne WL; van den Bergh ACM; Aben KKH; Somford DM; Bergman AM; Uyl-de Groot CA; Gerritsen WR; van den Eertwegh AJM
Eur Urol Focus; 2021 Jul; 7(4):788-796. PubMed ID: 32362484
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations.
Tsai AK; Kagalwalla S; Langer J; Le-Kumar T; Le-Kumar V; Antonarakis ES
Expert Opin Biol Ther; 2024; 24(1-2):51-62. PubMed ID: 38284349
[TBL] [Abstract][Full Text] [Related]
29. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
Scher HI; Graf RP; Schreiber NA; McLaughlin B; Lu D; Louw J; Danila DC; Dugan L; Johnson A; Heller G; Fleisher M; Dittamore R
Eur Urol; 2017 Jun; 71(6):874-882. PubMed ID: 27979426
[TBL] [Abstract][Full Text] [Related]
30. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996
[TBL] [Abstract][Full Text] [Related]
31. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
32. Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer.
Redman JM; Steinberg SM; Gulley JL
J Immunother Cancer; 2018 Sep; 6(1):91. PubMed ID: 30227893
[TBL] [Abstract][Full Text] [Related]
33. Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry.
Verry C; Vincendeau S; Massetti M; Blachier M; Vimont A; Bazil ML; Bernardini P; Pettré S; Timsit MO
Target Oncol; 2022 Jul; 17(4):441-451. PubMed ID: 35841526
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer.
Lorente D; Llacer C; Lozano R; de Velasco G; Romero-Laorden N; Rodrigo M; Sánchez-Iglesias Á; di Capua C; Castro E; Ferrer C; Sánchez-Hernández A; Olmos D
Eur Urol; 2021 Nov; 80(5):641-649. PubMed ID: 34373138
[TBL] [Abstract][Full Text] [Related]
35. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555
[TBL] [Abstract][Full Text] [Related]
36. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
[TBL] [Abstract][Full Text] [Related]
37. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
38. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
39. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
[TBL] [Abstract][Full Text] [Related]
40. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
